Emmessar Biotech & Nutrition Ltd.
BSE: EMMESSA · Commodity Chemicals
Limited coverage
We are not actively covering this company or have limited coverage today. Click to request coverage.
Snapshot
Unlock Emmessar Biotech & Nutrition Ltd.'s vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Emmessar Biotech and Nutrition Limited is an Indian entity focused on the research, development, and marketing of healthcare products, nutritional supplements, and specialized pharmaceutical formulations. The company operates a manufacturing facility in Taloja, Maharashtra, integrating traditional healthcare concepts with modern biotechnology.
Business Model
The company generates revenue by developing and marketing cost-effective healthcare solutions, skin care treatments, and nutritional additives for the domestic Indian market. It leverages its manufacturing capabilities in fine chemicals and pharmaceutical formulations to serve niche segments.
Growth Outlook
Growth is driven by the company's focus on expanding its niche presence in the Indian healthcare and biotechnology sectors. The firm aims to leverage its existing manufacturing infrastructure to scale the production of specialized pharmaceutical and nutritional products.
Key Risks
- Regulatory Compliance. The company is subject to stringent pharmaceutical and healthcare regulations in India, which may impact product approval timelines and operational costs.
- Market Competition. As a small-cap entity, the company faces intense competition from larger, well-capitalised pharmaceutical firms operating in the same healthcare and nutrition segments.
- Operational Concentration. Reliance on a single manufacturing facility in Taloja creates a concentration risk where any disruption to the site could significantly impact production capabilities.
- R&D Uncertainty. The business model relies on the successful development of healthcare products, which carries inherent risks regarding research outcomes and commercial viability.
Start your research today
Unlock AI insights, financials, peers and live data on Emmessar Biotech & Nutrition Ltd. and 5,000+ companies — free.
Key Metrics
REVENUE
₹0.37 Cr
TTM · standalone
NET PROFIT
₹0.47 Cr
TTM · standalone
EPS
₹0.96
TTM · standalone
RETURN ON EQUITY
6.0%
TTM · standalone
RETURN ON CAPITAL EMPLOYED
8.6%
TTM · standalone
P/E
25.8x
Q3 FY26 · standalone
EV/EBITDA
12.8x
Q3 FY26 · standalone
EBITDA MARGIN
232.4%
TTM · standalone
NET PROFIT MARGIN
133.3%
Q3 FY26 · standalone
DEBT TO EQUITY
0.0x
Q4 FY26 · standalone
Peers · Commodity Chemicals
| Company | Mkt Cap | P/E | EV/EBITDA | Rev Gr YoY | EBITDA Mgn | ROE | ROCE | 1Y Return |
|---|---|---|---|---|---|---|---|---|
Emmessar Biotech & Nutrition Ltd.EMMESSA | ₹12 Cr | 26.03 | 14.51 | -38.3% | 232.4% | 6.0% | 8.6% | -5.7% |
Blue Pearl Agriventures LimitedBPAGRI | ₹525 Cr | — | — | — | 2.7% | — | — | -92.2% |
Primo ChemicalsPRIMO | ₹517 Cr | 32.82 | 7.31 | -2.7% | 15.8% | 4.0% | 7.1% | -16.6% |
POCL EnterprisesPOEL | ₹460 Cr | 10.53 | 7.57 | — | 5.3% | 21.3% | 33.7% | -37.2% |
Mangalam OrganicMANORG | ₹437 Cr | 21.41 | 8.88 | 17.3% | 13.6% | 6.8% | 15.9% | -7.2% |
Lords Chloro Alkali LimitedLORDSCHLO | ₹402 Cr | 11.52 | 7.91 | 29.8% | 17.3% | 15.6% | 14.1% | -18.7% |
As of Q3 FY26
Financials
Emmessar Biotech & Nutrition Ltd.
BSE: EMMESSA · Commodity Chemicals
Limited coverage
We are not actively covering this company or have limited coverage today. Click to request coverage.
Snapshot
Unlock Emmessar Biotech & Nutrition Ltd.'s vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Emmessar Biotech and Nutrition Limited is an Indian entity focused on the research, development, and marketing of healthcare products, nutritional supplements, and specialized pharmaceutical formulations. The company operates a manufacturing facility in Taloja, Maharashtra, integrating traditional healthcare concepts with modern biotechnology.
Business Model
The company generates revenue by developing and marketing cost-effective healthcare solutions, skin care treatments, and nutritional additives for the domestic Indian market. It leverages its manufacturing capabilities in fine chemicals and pharmaceutical formulations to serve niche segments.
Growth Outlook
Growth is driven by the company's focus on expanding its niche presence in the Indian healthcare and biotechnology sectors. The firm aims to leverage its existing manufacturing infrastructure to scale the production of specialized pharmaceutical and nutritional products.
Key Risks
- Regulatory Compliance. The company is subject to stringent pharmaceutical and healthcare regulations in India, which may impact product approval timelines and operational costs.
- Market Competition. As a small-cap entity, the company faces intense competition from larger, well-capitalised pharmaceutical firms operating in the same healthcare and nutrition segments.
- Operational Concentration. Reliance on a single manufacturing facility in Taloja creates a concentration risk where any disruption to the site could significantly impact production capabilities.
- R&D Uncertainty. The business model relies on the successful development of healthcare products, which carries inherent risks regarding research outcomes and commercial viability.
Start your research today
Unlock AI insights, financials, peers and live data on Emmessar Biotech & Nutrition Ltd. and 5,000+ companies — free.
Key Metrics
REVENUE
₹0.37 Cr
TTM · standalone
NET PROFIT
₹0.47 Cr
TTM · standalone
EPS
₹0.96
TTM · standalone
RETURN ON EQUITY
6.0%
TTM · standalone
RETURN ON CAPITAL EMPLOYED
8.6%
TTM · standalone
P/E
25.8x
Q3 FY26 · standalone
EV/EBITDA
12.8x
Q3 FY26 · standalone
EBITDA MARGIN
232.4%
TTM · standalone
NET PROFIT MARGIN
133.3%
Q3 FY26 · standalone
DEBT TO EQUITY
0.0x
Q4 FY26 · standalone
Peers · Commodity Chemicals
As of Q3 FY26